RGDXQ Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (15 May 2023 @ 12:32):

Stats
Today's Volume	77 000.00
Average Volume	0.00
Market Cap	116.00
EPS	$-0.108 ( 2015-03-31 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Volume Correlation

Long: -0.48 (neutral)

Short: 0.00 (neutral)

Signal:(51.968) Neutral

Response Genetics, Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Response Genetics, Inc Correlation - Currency/Commodity

0.00
( neutral )

Response Genetics, Inc Financials

Annual	2015
Revenue:	$18.04M
Gross Profit:	$3.94M (21.85 %)
EPS:	$-0.521

FY	2015
Revenue:	$18.04M
Gross Profit:	$3.94M (21.85 %)
EPS:	$-0.521

FY	2014
Revenue:	$16.72M
Gross Profit:	$6.71M (40.12 %)
EPS:	$-0.350

FY	2013
Revenue:	$19.80M
Gross Profit:	$9.35M (47.20 %)
EPS:	$-0.240

Financial Reports:

No articles found.

Response Genetics, Inc

Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.